It's How Medicine Should Be®

Physician Profile

-or-

call (888) 352-RUSH for help arranging an appointment

David J. Sher, MD, MPH

Specialty:
  • Oncology, Radiation
Board Certification:
  • Radiation Oncology
Faculty Rank: Assistant Professor
Medical or Graduate Education: Harvard Medical School
Residency: Harvard Radiation Oncology Program
Clinical Expertise:
  • Carcinoid tumor
  • Head and neck tumors
  • Lung cancer
  • Radiation therapy
  • Sinus and skull base tumors
  • Stereotactic body radiotherapy
Research Interests:
  • Comparative effectiveness research
  • Cost effectiveness analysis
  • Novel treatments for lung cancer
  • Novel treatments for head and neck cancer
Google Map
  • University Radiation Medicine
  • Woman's Board Center for Radiation Therapy
  • 500 S. Paulina St.
  • Ground Floor
  • Chicago, IL  60612
  • Phone: (312) 942-6817
  • Fax: (312) 942-2339
  • View Larger MapDriving Directions

Below is a list of scientific publications for which this practitioner was either the primary author or a contributor. Citations come from PubMed, a database of biomedical literature, life science journals and online books. PubMed is a service of the US Library of Medicine at the National Institutes of Health. Click on the title of the cited work for more information (this will take you directly to PubMed.gov). Listings go back five years.

  1. Patterns-of-failure after helical tomotherapy-based chemoradiotherapy for head and neck cancer: implications for CTV margin, elective nodal dose and bilateral parotid sparing.
    Dandekar V, Morgan T, Turian J, Fidler MJ, Showel J, Nielsen T, Coleman J, Diaz A, Sher DJ
    Oral Oncol.
    2014 May
    50(5):520-6.
  2. The Effect of Radiotherapy Dose on Survival in Stage III Non-Small-Cell Lung Cancer Patients Undergoing Definitive Chemoradiotherapy.
    Koshy M, Malik R, Sher DJ, Spiotto M, Mahmood U, Ayodgan B, Weichselbaum RR
    Clin Lung Cancer
    2014 Jun 2
  3. Prevalence and Predictors of Neoadjuvant Therapy for Stage IIIA Non-Small Cell Lung Cancer in the National Cancer Database: Importance of Socioeconomic Status and Treating Institution.
    Sher DJ, Liptay MJ, Fidler MJ
    Int. J. Radiat. Oncol. Biol. Phys.
    2014 Jun 1
    89(2):303-12.
  4. Decision analysis and cost-effectiveness analysis for comparative effectiveness research-a primer.
    Sher DJ, Punglia RS
    Semin Radiat Oncol
    2014 Jan
    24(1):14-24.
  5. Aggressive therapy for patients with non-small cell lung carcinoma and synchronous brain-only oligometastatic disease is associated with long-term survival.
    Gray PJ, Mak RH, Yeap BY, Cryer SK, Pinnell NE, Christianson LW, Sher DJ, Arvold ND, Baldini EH, Chen AB, Kozono DE, Swanson SJ, Jackman DM, Alexander BM
    Lung Cancer
    2014 Aug
    85(2):239-44.
  6. Systematic review of the cost effectiveness of radiation therapy for prostate cancer from 2003 to 2013.
    Amin NP, Sher DJ, Konski AA
    Appl Health Econ Health Policy
    2014 Aug
    12(4):391-408.
  7. Efficacy and Tolerability of Palliative Split-Course Thoracic Chemoradiotherapy for Symptomatic Non-Small Cell Lung Cancer.
    Dandekar VK, Young J, Kiel K, Bonomi P, Fidler MJ, Batus M, Sher DJ
    Am. J. Clin. Oncol.
    2014 Apr 28
  8. Influence of conformal radiotherapy technique on survival after chemoradiotherapy for patients with stage III non-small cell lung cancer in the National Cancer Data Base.
    Sher DJ, Koshy M, Liptay MJ, Fidler MJ
    Cancer
    2014 Apr 1
  9. Value considerations in the treatment of head and neck cancer: radiation, chemotherapy, and supportive care.
    Baxi SS, Sher DJ, Pfister DG
    Am Soc Clin Oncol Educ Book
    2014
    34:e296-303.
  10. Low incidence of chest wall pain with a risk-adapted lung stereotactic body radiation therapy approach using three or five fractions based on chest wall dosimetry.
    Coroller TP, Mak RH, Lewis JH, Baldini EH, Chen AB, Colson YL, Hacker FL, Hermann G, Kozono D, Mannarino E, Molodowitch C, Wee JO, Sher DJ, Killoran JH
    PLoS ONE
    2014
    9(4):e94859.
  11. Patterns of regional failure in stage III non-small cell lung cancer treated with neoadjuvant chemoradiation therapy and resection.
    Garg S, Gielda BT, Turian JV, Liptay M, Warren WH, Bonomi P, Sher DJ
    Pract Radiat Oncol
    2013 Oct-Dec
    3(4):287-93.
  12. Cost-effectiveness of stereotactic body radiation therapy versus surgical resection for stage I non-small cell lung cancer.
    Shah A, Hahn SM, Stetson RL, Friedberg JS, Pechet TT, Sher DJ
    Cancer
    2013 May 29
  13. Death from high-risk prostate cancer versus cardiovascular mortality with hormonal therapy: A decision analysis.
    Lester-Coll NH, Goldhaber SZ, Sher DJ, D'Amico AV.
    Cancer. 2013
    2013 Feb 7. doi: 10.1002/cncr.27980. [Epub ahead of print]
  14. Salivary gland tumors treated with adjuvant intensity-modulated radiotherapy with or without concurrent chemotherapy.
    Schoenfeld JD, Sher DJ, Norris CM Jr, Haddad RI, Posner MR, Balboni TA, Tishler RB.
    Int J Radiat Oncol Biol Phys. 2012
    2012 Jan 1
    82(1):308-14. doi: 10.1016/j.ijrobp.2010.09.042. Epub 2010 Nov 13.
  15. Clinical utility of 4D FDG-PET/CT scans in radiation treatment planning.
    Aristophanous M, Berbeco RI, Killoran JH, Yap JT, Sher DJ, Allen AM, Larson E, Chen AB.
    Int J Radiat Oncol Biol Phys. 2012
    2012 Jan 1
    82(1):e99-105. doi: 10.1016/j.ijrobp.2010.12.060. Epub 2011 Mar 4.
  16. Primary radiotherapy versus radical prostatectomy for high-risk prostate cancer: a decision analysis.
    Parikh R, Sher DJ.
    Cancer. 2012
    2012 Jan 1
    118(1):258-67. doi: 10.1002/cncr.26272. Epub 2011 Jun 30.
  17. Cost-effectiveness Analysis of SBRT Versus IMRT for Low-risk Prostate Cancer.
    Sher DJ, Parikh R, Mays-Jackson S, Punglia RS.
    Am J Clin Oncol. 2012
    2012 Dec 27. [Epub ahead of print]
  18. Prognostic Significance of Weight Gain During Definitive Chemoradiotherapy for Locally Advanced Non-Small-Cell Lung Cancer.
    Sher DJ, Gielda BT, Liptay MJ, Warren WH, Batus M, Fidler MJ, Garg S, Bonomi P.
    Clin Lung Cancer. 2012
    2012 Dec 20. doi:pii: S1525-7304(12)00263-X. 10.1016/j.cllc.2012.10.009. [Epub ahead of print]
  19. Treatment of oral cavity squamous cell carcinoma with adjuvant or definitive intensity-modulated radiation therapy.
    Sher DJ, Thotakura V, Balboni TA, Norris CM Jr, Haddad RI, Posner MR, Lorch J, Goguen LA, Annino DJ, Tishler RB.
    Int J Radiat Oncol Biol Phys. 2011
    2011 Nov 15
    81(4):e215-22. doi: 10.1016/j.ijrobp.2011.02.023. Epub 2011 Apr 29.
  20. Predictors of IMRT and conformal radiotherapy use in head and neck squamous cell carcinoma: a SEER-Medicare analysis.
    Sher DJ, Neville BA, Chen AB, Schrag D.
    Int J Radiat Oncol Biol Phys. 2011
    2011 Nov 15
    81(4):e197-206. doi: 10.1016/j.ijrobp.2011.02.007. Epub 2011 May 17.
  21. Survival outcomes after radiation therapy for stage III non-small-cell lung cancer after adoption of computed tomography-based simulation.
    Chen AB, Neville BA, Sher DJ, Chen K, Schrag D.
    J Clin Oncol. 2011
    2011 Jun 10
    29(17):2305-11. doi: 10.1200/JCO.2010.33.4466. Epub 2011 May 2.
  22. Effect of respiratory trace shape on optimal treatment margin.
    Winey B, Wagar M, Ebe K, Popple R, Lingos T, Sher D, Court L.
    Med Phys. 2011
    2011 Jun
    38(6):3125-9.
  23. Cost-effectiveness analysis of stereotactic body radiotherapy and radiofrequency ablation for medically inoperable, early-stage non-small cell lung cancer.
    Sher DJ, Wee JO, Punglia RS.
    Int J Radiat Oncol Biol Phys. 2011
    2011 Dec 1
    81(5):e767-74. doi: 10.1016/j.ijrobp.2010.10.074. Epub 2011 Feb 6.
  24. Relationship between radiation treatment time and overall survival after induction chemotherapy for locally advanced head-and-neck carcinoma: a subset analysis of TAX 324.
    Sher DJ, Posner MR, Tishler RB, Sarlis NJ, Haddad RI, Holupka EJ, Devlin PM.
    Int J Radiat Oncol Biol Phys. 2011
    2011 Dec 1
    81(5):e813-8. doi: 10.1016/j.ijrobp.2010.12.005. Epub 2011 Feb 6.
  25. Efficacy and toxicity of chemoradiotherapy using intensity-modulated radiotherapy for unknown primary of head and neck.
    Sher DJ, Balboni TA, Haddad RI, Norris CM Jr, Posner MR, Wirth LJ, Goguen LA, Annino D, Tishler RB.
    Int J Radiat Oncol Biol Phys. 2011
    2011 Aug 1
    80(5):1405-11. doi: 10.1016/j.ijrobp.2010.04.029. Epub 2010 Dec 20.
  26. Sunitinib-induced pseudoprogression after whole-brain radiotherapy for metastatic renal cell carcinoma.
    Kelly PJ, Weiss SE, Sher DJ, Perez-Atayde AR, Dal Cin P, Choueiri TK.
    J Clin Oncol. 2010
    2010 Sep 1
    28(25):e433-5. doi: 10.1200/JCO.2009.26.8193. Epub 2010 Jun 14. No abstract available.
  27. Utilizing computed tomography as a road map for designing selective and superselective neck dissection after chemoradiotherapy.
    Goguen LA, Chapuy CI, Sher DJ, Israel DA, Blinder RA, Norris CM, Tishler RB, Haddad RI, Annino DJ.
    Otolaryngol Head Neck Surg. 2010
    2010 Sep
    143(3):367-74. doi: 10.1016/j.otohns.2010.04.020.
  28. Efficacy and toxicity of reirradiation using intensity-modulated radiotherapy for recurrent or second primary head and neck cancer.
    Sher DJ, Haddad RI, Norris CM Jr, Posner MR, Wirth LJ, Goguen LA, Annino D, Balboni T, Allen A, Tishler RB.
    Cancer. 2010
    2010 Oct 15
    116(20):4761-8. doi: 10.1002/cncr.25305.
  29. Cost-effectiveness studies in radiation therapy.
    Sher DJ.
    Expert Rev Pharmacoecon Outcomes Res. 2010
    2010 Oct
    10(5):567-82. doi: 10.1586/erp.10.51. Review.
  30. Cost-effectiveness of CT and PET-CT for determining the need for adjuvant neck dissection in locally advanced head and neck cancer.
    Sher DJ, Tishler RB, Annino D, Punglia RS.
    Ann Oncol.
    2010 May
    21(5):1072-7
  31. Prognostic significance of mid- and post-ABVD PET imaging in Hodgkin's lymphoma: the importance of involved-field radiotherapy.
    Sher DJ, Mauch PM, Van Den Abbeele A, LaCasce AS, Czerminski J, Ng AK.
    Ann Oncol.
    2009 Nov
    20(11):1848-53
  32. Partial-breast irradiation versus whole-breast irradiation for early-stage breast cancer: a cost-effectiveness analysis.
    Sher DJ, Wittenberg E, Suh WW, Taghian AG, Punglia RS.
    Int J Radiat Oncol Biol Phys. 2009
    2009 Jun 1
    74(2):440-6. doi: 10.1016/j.ijrobp.2008.08.015. Epub 2008 Oct 27.
  33. Absence of relationship between steroid hormone levels and prostate cancer tumor grade.
    Sher DJ, Mantzoros C, Jacobus S, Regan MM, Lee GS, Oh WK.
    Urology. 2009
    2009 Feb
    73(2):356-61; discussion 361-2. doi: 10.1016/j.urology.2008.07.068. Epub 2008 Nov 26.
  34. Relationship between serum adiponectin and prostate cancer grade.
    Sher DJ, Oh WK, Jacobus S, Regan MM, Lee GS, Mantzoros C.
    Prostate. 2008
    2008 Oct 1
    68(14):1592-8. doi: 10.1002/pros.20823.
  35. The added value of concurrently administered temozolomide versus adjuvant temozolomide alone in newly diagnosed glioblastoma.
    Sher DJ, Henson JW, Avutu B, Hochberg FH, Batchelor TT, Martuza RL, Barker FG 2nd, Loeffler JS, Chakravarti A.
    J Neurooncol. 2008
    2008 May
    88(1):43-50. doi: 10.1007/s11060-008-9530-8. Epub 2008 Jan 30.
  36. Partial breast irradiation versus whole breast radiotherapy for early-stage breast cancer: a decision analysis.
    Sher DJ, Wittenberg E, Taghian AG, Bellon JR, Punglia RS.
    Int J Radiat Oncol Biol Phys. 2008
    2008 Feb 1
    70(2):469-76. Epub 2007 Oct 29.
  37. Multi-institutional review of repeat irradiation of chest wall and breast for recurrent breast cancer.
    Wahl AO, Rademaker A, Kiel KD, Jones EL, Marks LB, Croog V, McCormick BM, Hirsch A, Karkar A, Motwani SB, Tereffe W, Yu TK, Sher D, Silverstein J, Kachnic LA, Kesslering C, Freedman GM, Small W Jr.
    Int J Radiat Oncol Biol Phys. 2008
    2008 Feb 1
    70(2):477-84. Epub 2007 Sep 14.
  • (If you cannot play the video, you may need to update to the latest version of Adobe Flash Player.)
  • View Transcript